Literature DB >> 32142099

Variations in incidence of venous thromboembolism in low-, middle-, and high-income countries.

Deborah M Siegal1,2, John W Eikelboom1,2, Shun Fu Lee1, Sumathy Rangarajan1, Jackie Bosch1,2, Jun Zhu3, Salim Yusuf1,2.   

Abstract

AIMS: To examine the rates of venous thromboembolism (VTE) in high-income, upper middle-income, and lower middle/low-income countries (World Bank Classification). METHODS AND
RESULTS: We examined the rates of VTE in high-income, upper middle-income, and lower middle/low-income countries (World Bank Classification) in a cohort derived from four prospective international studies (PURE, HOPE-3, ORIGIN, and COMPASS). The primary outcome was a composite of pulmonary embolism, deep vein thrombosis, and thrombophlebitis. We calculated age- and sex-standardized incidence rates (per 1000 person-years) and used a Cox frailty model adjusted for covariates to examine associations between the incidence of VTE and country income level. A total of 215 307 individuals (1.5 million person-years of follow-up) from high-income (n = 60 403), upper middle-income (n = 42 066), and lower middle/low-income (n = 112 838) countries were included. The age- and sex-standardized incidence rates of VTE per 1000 person-years in high-, upper middle-, and lower middle/low-income countries were 0.87, 0.25, and 0.06, respectively. After adjusting for age, body mass index (BMI), smoking, antiplatelet therapy, anticoagulant therapy, education level, ethnicity, and incident cancer diagnosis or hospitalization, individuals from high-income and upper middle-income countries had a significantly higher risk of VTE than those from lower middle/low-income countries [hazard ratio (HR) 3.57, 95% confidence interval (CI) 2.40-5.30 and HR 2.27, 95% CI 1.59-3.23, respectively]. The effect of country income level on VTE risk was markedly stronger in people with a lower BMI, hypertension, diabetes, non-White ethnicity, and higher education.
CONCLUSION: The rates of VTE are substantially higher in high-income than in low-income countries. The factors underlying the increased VTE risk in higher-income countries remain unknown. Published on behalf of the European Society of Cardiology. All rights reserved.
© The Author(s) 2020. For permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  Country income status; Global; Venous thromboembolism

Mesh:

Year:  2021        PMID: 32142099     DOI: 10.1093/cvr/cvaa044

Source DB:  PubMed          Journal:  Cardiovasc Res        ISSN: 0008-6363            Impact factor:   10.787


  7 in total

1.  Treatment and secondary prophylaxis of venous thromboembolism in cancer patients.

Authors:  Nadeen T Ali; Annie Young
Journal:  Support Care Cancer       Date:  2022-05-19       Impact factor: 3.359

Review 2.  Cancer-associated venous thromboembolism.

Authors:  Alok A Khorana; Nigel Mackman; Anna Falanga; Ingrid Pabinger; Simon Noble; Walter Ageno; Florian Moik; Agnes Y Y Lee
Journal:  Nat Rev Dis Primers       Date:  2022-02-17       Impact factor: 65.038

3.  Do Inpatients Receive Risk-Based Prophylactic Treatment for Thrombotic Events?

Authors:  Armin Nemani; Constantin von Zur Mühlen; Friederike Steffen; Johannes Schulte; Christoph Bode; Marvin Krohn-Grimberghe
Journal:  Clin Appl Thromb Hemost       Date:  2021 Jan-Dec       Impact factor: 2.389

4.  Knowledge and Behavior toward Venous Thromboembolism Event Prophylaxis and Treatment Protocols among Medical Interns in Riyadh.

Authors:  Zohair Al Aseri; Jumanah Meshari Muammar; Najd Fahad Aldakkan; Afnan A Alhazmi; Hadeel Hamad Albraik; Aeshah Abdullah Alasmari; Lyla Mohammed Ashry; Shaik S Ahmed; Aamer Aleem
Journal:  Biomed Res Int       Date:  2022-07-20       Impact factor: 3.246

5.  Trend and causes of maternal death, stillbirth and neonatal death over seven decades in Hong Kong.

Authors:  Ka Wang Cheung; Mimi Tin Yan Seto; Weilan Wang; Chi Tao Ng; William Wing Kee To; Ernest Hung Yu Ng
Journal:  Lancet Reg Health West Pac       Date:  2022-07-06

6.  Cystathionine β-synthase deficiency in the E-HOD registry-part I: pyridoxine responsiveness as a determinant of biochemical and clinical phenotype at diagnosis.

Authors:  Viktor Kožich; Jitka Sokolová; Andrew A M Morris; Markéta Pavlíková; Florian Gleich; Stefan Kölker; Jakub Krijt; Carlo Dionisi-Vici; Matthias R Baumgartner; Henk J Blom; Martina Huemer
Journal:  J Inherit Metab Dis       Date:  2020-12-28       Impact factor: 4.982

7.  Global reporting of pulmonary embolism-related deaths in the World Health Organization mortality database: Vital registration data from 123 countries.

Authors:  Stefano Barco; Luca Valerio; Andrea Gallo; Giacomo Turatti; Seyed Hamidreza Mahmoudpour; Walter Ageno; Lana A Castellucci; Gabriela Cesarman-Maus; Henry Ddungu; Erich Vinicius De Paula; Mert Dumantepe; Samuel Z Goldhaber; Maria Cecilia Guillermo Esposito; Frederikus A Klok; Nils Kucher; Claire McLintock; Fionnuala Ní Áinle; Paolo Simioni; David Spirk; Alex C Spyropoulos; Tetsumei Urano; Zhen-Guo Zhai; Beverley J Hunt; Stavros V Konstantinides
Journal:  Res Pract Thromb Haemost       Date:  2021-06-15
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.